{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:00:17Z","timestamp":1790694017176,"version":"4.1.0"},"reference-count":19,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,9,14]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Serotonin syndrome is a potentially life-threatening toxicity diagnosed clinically and characterised by a variable clinical presentation.<\/jats:p>\n                  <jats:p>Spontaneous clonus in a patient receiving a serotonergic antidepressant should prompt immediate consideration of serotonin syndrome, even when the prescribed dose and measured drug concentrations are not high.<\/jats:p>\n                  <jats:p>Unexpected toxicity at low doses should also prompt a systematic review of pharmacokinetic interactions, organ function and pharmacogenetic susceptibility.<\/jats:p>\n                  <jats:p>A man in his late 70s with transthyretin amyloidosis experienced at least five episodes of serotonin syndrome (four on venlafaxine immediate release (IR) \u226475 mg\/day), all meeting Hunter criteria.<\/jats:p>\n                  <jats:p>Trough plasma concentrations revealed markedly elevated exposure relative to the administered venlafaxine dose. At the highest measured dose, venlafaxine and O-desmethylvenlafaxine (ODV) concentrations were 377 nmol\/L and 1330 nmol\/L, respectively, yielding an active moiety concentration of 1707 nmol\/L. All trough concentrations exceeded the expected values for a 75 mg dose (venlafaxine ~38 nmol\/L, ODV ~330 nmol\/L, active moiety ~365 nmol\/L), while remaining within the therapeutic reference range of approximately 518\u20132220 nmol\/L. The metabolite to parent ratio was low, suggestive of reduced CYP2D6 activity.<\/jats:p>","DOI":"10.1136\/bcr-2026-273316","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:32:34Z","timestamp":1790692354000},"page":"e273316","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent serotonin syndrome during low-dose venlafaxine treatment in a patient with reduced CYP2D6 activity"],"prefix":"10.1136","volume":"19","author":[{"given":"Lara Nora Ananda","family":"Bouti","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Graenicher","sequence":"additional","affiliation":[{"name":"Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-6179","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Simona","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"El Rida El Masri","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Oncology, CHUV, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Flora","family":"Samer","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland"},{"name":"School of Pharmaceutical Sciences, Faculty of Sciences, University of Geneva, Geneva, Switzerland"},{"name":"Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092907202054000_19.9.e273316.1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2217\/pgs-2019-0031","article-title":"Venlafaxine pharmacogenetics: a comprehensive review","volume":"20","author":"Suwa\u0142a","year":"2019","journal-title":"Pharmacogenomics"},{"key":"2026092907202054000_19.9.e273316.2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bcpt.13912","article-title":"Serotonin syndrome-A focused review","volume":"133","author":"Mikkelsen","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026092907202054000_19.9.e273316.3","first-page":"452","article-title":"Serotonin Syndrome\/Serotonin Toxicity","volume":"37","author":"Talton","year":"2020","journal-title":"Fed Pract"},{"key":"2026092907202054000_19.9.e273316.4","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg109"},{"key":"2026092907202054000_19.9.e273316.5","doi-asserted-by":"publisher","DOI":"10.1054\/mehy.2000.1047"},{"key":"2026092907202054000_19.9.e273316.6","first-page":"2086","article-title":"[b]Syndrome[\/b] s\u00e9rotoninergique: mise au point et revue des cas annonc\u00e9s en Suisse","volume":"8","author":"Chassot","year":"2012","journal-title":"Rev Med Suisse"},{"key":"2026092907202054000_19.9.e273316.7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00213-023-06484-7","article-title":"Venlafaxine\u2019s therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis","volume":"241","author":"Lense","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"key":"2026092907202054000_19.9.e273316.8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1773677","article-title":"Pharmacogenetics of antidepressant response: a focused review on CYP2C19, CYP2D6, SLC6A4, and HTR2A polymorphisms","volume":"17","author":"Blambila","year":"2026","journal-title":"Front Pharmacol"},{"key":"2026092907202054000_19.9.e273316.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2010.04.004"},{"key":"2026092907202054000_19.9.e273316.10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/a-2860-7861","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects","volume":"59","author":"Hart","year":"2026","journal-title":"Pharmacopsychiatry"},{"key":"2026092907202054000_19.9.e273316.11","unstructured":"Swissmedic . AIPS: recherche individuelle. Berne: Swissmedic; 2026. Available: https:\/\/swissmedicinfo-pro.ch\/?Lang=FR"},{"key":"2026092907202054000_19.9.e273316.12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JCP.0000000000001174","article-title":"The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort","volume":"40","author":"Kringen","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"2026092907202054000_19.9.e273316.13","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/pgs-2019-0083","article-title":"Pharmacogenomics in the clinic: genetic polymorphism contributing to venlafaxine-associated heart failure","volume":"20","author":"Singh","year":"2019","journal-title":"Pharmacogenomics"},{"key":"2026092907202054000_19.9.e273316.14","doi-asserted-by":"crossref","first-page":"1000109","DOI":"10.4172\/2572-0791.1000109","article-title":"Pharmacogenetics of antidepressants, a review of significant genetic variants in different populations","volume":"02","author":"Barron","year":"2017","journal-title":"Clin Depress"},{"key":"2026092907202054000_19.9.e273316.15","doi-asserted-by":"publisher","DOI":"10.1002\/CPT.2903"},{"key":"2026092907202054000_19.9.e273316.16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/jcpt.13507","article-title":"Effects of age and gender on the cytochrome P450 2D6 activity in a Korean population","volume":"46","author":"Park","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2026092907202054000_19.9.e273316.17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/17425255.2015.1041919","article-title":"Measuring pharmacogenetics in special groups: geriatrics","volume":"11","author":"Seripa","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026092907202054000_19.9.e273316.18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11096-012-9666-7","article-title":"A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge","volume":"34","author":"Decoutere","year":"2012","journal-title":"Int J Clin Pharm"},{"key":"2026092907202054000_19.9.e273316.19","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-832598"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-273316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:32:36Z","timestamp":1790692356000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-273316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bcr-2026-273316"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-273316","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}